Regulation of sarcopenia and muscle dysfunction by nitric oxide

一氧化氮调节肌肉减少症和肌肉功能障碍

基本信息

  • 批准号:
    7470590
  • 负责人:
  • 金额:
    $ 32.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-15 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Sarcopenia, the loss of muscle mass during aging, is an inevitable consequence of aging that takes a tremendous toll on the quality of life of the elderly, and predisposes the aging population to injuries that can be further debilitating. Societal cost of sarcopenia and associated injuries and complications is huge, and will grow rapidly as the United States demographic rapidly shifts toward a more senior population. However, the shortage of mechanistic knowledge concerning the causes of sarcopenia has prevented more specific interventions to slow the process of muscle wasting. Our findings show that aging muscle undergoes a dramatic reduction in neuronal nitric oxide synthase (nNOS) and that restoring nNOS to aging muscle prevents sarcopenia in mice. Our goal in this investigation is to identify the mechanisms through which nNOS protects against sarcopenia. Based upon our preliminary studies and the findings of others, we have generated the hypothesis that nNOS-derived NO slows sarcopenia through two processes: 1) inhibition of muscle proteases calpain-1, calpain-2 and caspase-3, to reduce proteolysis of myofibrillar proteins, and 2) inhibition in the production of inflammatory cytokines that are able to promote muscle wasting, especially tumor necrosis factor-alpha (TNFa). We will address this hypothesis in aging mouse models by testing whether muscle protease inhibition by NO-mediated S-nitrosylation occurs during muscle aging. Whether calpain inhibition is sufficient to reduce sarcopenia will be tested in mice that have been genetically-modified to produce elevated levels of the calpain inhibitor, calpastatin, in muscle. We will also identify the specific proteolytic modifications of major muscle proteins in myofibrils that are caused by calpain-2 or caspase-3. In other experiments, we will test whether manipulations of NO production by muscle can reduce the production of inflammatory cytokines, or muscle invasion by inflammatory cells. In addition, we will determine whether reducing the production of pro-inflammatory cytokines is sufficient to slow sarcopenia by testing whether muscle wasting is reduced in aging, TNFa null mutant on interferon-gamma null mice. We anticipate that the results of this investigation can provide new insights into potential therapeutic strategies to reduce sarcopenia.
描述(由申请人提供):骨骼肌减少症,即在衰老过程中肌肉量的减少,是衰老不可避免的结果,对老年人的生活质量造成巨大影响,并使老年人容易受伤,从而进一步使人衰弱。肌肉减少症及其相关损伤和并发症的社会成本是巨大的,随着美国人口结构迅速向老年人口转变,这一成本将迅速增长。然而,缺乏关于肌肉减少症原因的机制知识阻碍了更具体的干预措施来减缓肌肉萎缩的过程。我们的研究结果表明,衰老肌肉中的神经元一氧化氮合酶(nNOS)急剧减少,而将nNOS恢复到衰老肌肉中可以预防小鼠的肌肉减少症。我们这项研究的目的是确定nNOS预防肌肉减少症的机制。根据我们的初步研究和其他人的发现,我们提出了nnos衍生的NO通过两个过程减缓肌肉减少症的假设:1)抑制肌肉蛋白酶calpain-1, calpain-2和caspase-3,以减少肌纤维蛋白的蛋白质水解;2)抑制能够促进肌肉萎缩的炎症细胞因子的产生,特别是肿瘤坏死因子- α (TNFa)。我们将在衰老小鼠模型中通过测试no介导的s -亚硝基化是否在肌肉衰老过程中发生肌肉蛋白酶抑制来验证这一假设。钙蛋白酶抑制剂是否足以减少肌肉减少症将在经过基因改造的小鼠身上进行测试,这些小鼠在肌肉中产生高水平的钙蛋白酶抑制剂(钙pastatin)。我们还将确定由calpain-2或caspase-3引起的肌原纤维中主要肌肉蛋白的特异性蛋白水解修饰。在其他实验中,我们将测试操纵肌肉产生NO是否可以减少炎症细胞因子的产生,或炎症细胞对肌肉的侵袭。此外,我们将通过在干扰素- γ缺失小鼠上测试衰老是否会减少肌肉萎缩,从而确定减少促炎细胞因子的产生是否足以减缓肌肉减少症。我们期望这项研究的结果可以为减少肌肉减少症的潜在治疗策略提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES G TIDBALL其他文献

JAMES G TIDBALL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES G TIDBALL', 18)}}的其他基金

Novel mechanisms regulating muscle growth and regeneration: elucidating the Klotho/Jmjd3/Wnt axis
调节肌肉生长和再生的新机制:阐明 Klotho/Jmjd3/Wnt 轴
  • 批准号:
    10402823
  • 财政年份:
    2020
  • 资助金额:
    $ 32.45万
  • 项目类别:
Novel mechanisms regulating muscle growth and regeneration: elucidating the Klotho/Jmjd3/Wnt axis
调节肌肉生长和再生的新机制:阐明 Klotho/Jmjd3/Wnt 轴
  • 批准号:
    10617378
  • 财政年份:
    2020
  • 资助金额:
    $ 32.45万
  • 项目类别:
Developing co-stimulatory blockade as a therapeutic strategy for Duchenne muscular dystrophy
开发共刺激阻滞作为杜氏肌营养不良症的治疗策略
  • 批准号:
    10201772
  • 财政年份:
    2019
  • 资助金额:
    $ 32.45万
  • 项目类别:
Developing co-stimulatory blockade as a therapeutic strategy for Duchenne muscular dystrophy
开发共刺激阻滞作为杜氏肌营养不良症的治疗策略
  • 批准号:
    10650296
  • 财政年份:
    2019
  • 资助金额:
    $ 32.45万
  • 项目类别:
Developing co-stimulatory blockade as a therapeutic strategy for Duchenne muscular dystrophy
开发共刺激阻滞作为杜氏肌营养不良症的治疗策略
  • 批准号:
    10438734
  • 财政年份:
    2019
  • 资助金额:
    $ 32.45万
  • 项目类别:
Developing co-stimulatory blockade as a therapeutic strategy for Duchenne muscular dystrophy
开发共刺激阻滞作为杜氏肌营养不良症的治疗策略
  • 批准号:
    10016862
  • 财政年份:
    2019
  • 资助金额:
    $ 32.45万
  • 项目类别:
Targeting Therapeutic Molecules to Dystrophic Muscle via the Immune System
通过免疫系统将治疗分子靶向营养不良性肌肉
  • 批准号:
    8769288
  • 财政年份:
    2014
  • 资助金额:
    $ 32.45万
  • 项目类别:
Myeloid-cell mediated mechanisms driving muscle growth and regeneration
骨髓细胞介导的肌肉生长和再生机制
  • 批准号:
    8671019
  • 财政年份:
    2014
  • 资助金额:
    $ 32.45万
  • 项目类别:
Immune cell regulation of the regeneration of dystrophic muscle
免疫细胞对营养不良性肌肉再生的调节
  • 批准号:
    9118073
  • 财政年份:
    2014
  • 资助金额:
    $ 32.45万
  • 项目类别:
Myeloid-cell mediated mechanisms driving muscle growth and regeneration
骨髓细胞介导的肌肉生长和再生机制
  • 批准号:
    9062860
  • 财政年份:
    2014
  • 资助金额:
    $ 32.45万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.45万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了